High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!

Actavis

Actavis’ U.S. Generics business is the dominant source of revenue for the Company with approximately 84% of total generic net revenue coming from the Company’s business in this market. The Company is focused on maintaining a leading position in the U.S. generics market, where it currently holds approximately 10% market share. In 2011, Actavis expanded its U.S. generic product line with the launch of 18 generic products. In addition to the generic versions of CONCERTA® and LIPITOR®, the Company launched generics of Famvir®, KADIAN®, Keppra XR®, AMRIX®, and new oral contraceptives including AmethiaTM (a generic version of SEASONIQUE®), Amethia®Lo (a generic version of Lo SEASONIQUE®), and AmethystTM (a generic version of Lybrel®). In 2011, the Company held a 36% share of the U.S. market in generic oral contraceptives with more than 30 product formulations. During the year, the Company announced the initiation of a number of patent challenges, including challenges to OxyContin®, Vigamox®, Welchol®, Viagra®, Pataday™, AVODART®, Vyvanse®, JALYN™, EMBEDA®, Daytrana®, Atelvia™, and Exelon®.

Actavis >

  • Morris Corporate Center III
  • 400 Interpace Parkway
  • Parsippany, NJ 07054 USA
  • Tel: +1-862-261-7000
  • Website:

Get direction from

Go!